A randomized double blind placebo controlled study to evaluate the modulation of cognitive functions in Parkinson's subjects by sildenafil.
Phase of Trial: Phase III
Latest Information Update: 16 Sep 2009
At a glance
- Drugs Sildenafil (Primary)
- Indications Mild cognitive impairment; Parkinson's disease
- Focus Therapeutic Use
- Acronyms SCOPE
- Sponsors Pfizer
- 07 Sep 2006 New trial record.